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Abstract:  The  present  study  was  designed  to  investigate  the  combined  effects  of 
cyclooxygenase  (COX)-1  and  COX-2  selective  inhibitors  on  human  ovarian  SKOV-3 
carcinoma cells xenograft-bearing mice. The animals were treated with 3 mg/kg SC-560 
(a COX-1  selective  inhibitor)  alone,  25  mg/kg  celecoxib  (a  COX-2  selective  inhibitor) 
alone, or SC-560/celecoxib by gavage, twice a day for three weeks. To test the mechanism 
of inhibition of tumor growth by COX selective inhibitors, the index of proliferating cells 
in tumor tissues was determined by immunostaining and the index of apoptotic cells by the 
terminal-deoxynucleotidyl-transferase-mediated  deoxyuridine  triphosphate  nick  end 
labeling (TUNEL) method. The inhibitory rate on tumor growth in the combination group 
was  35.54%  which  is  significant  statistically  compared  with  that  of  the  control  group  
(P < 0.05). In the combination group, the index of cell proliferation and apoptosis were 
12.40% and 51.03% respectively, which are significant statistically compared with those of 
the control group (22.56%, 19.07%, all P < 0.05). These studies indicate that synergism 
between two COX inhibitors and inhibitor combination treatment has particular potential 
for chemoprevention of ovarian cancer growth. 
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1. Introduction 
Ovarian cancer represents the leading cause of death among gynecological malignancies. Despite 
recent advances in surgery and chemotherapy, improvement in long-term survival of these patients has 
been slight [1]. Chemical carcinogenesis experiments and epidemiological and clinical studies have 
collectively identified prostaglandins and their rate-limiting enzymes, cyclooxygenase (COX)-1 and 
COX-2, as molecules involved in the onset and progression of a variety of malignancies [2]. Research 
primarily  focusing  on  colorectal  cancer  has  provided  strong  evidence  that  nonsteroidal 
anti-inflammatory  steroids  (NSAID)  are  effective  in  both  cancer  prevention  and  treatment  of 
established tumors [3]. NSAIDs block arachidonic acid metabolism by inhibiting COX, the enzyme 
that catalyze the rate-limiting step, and thus reducing levels of prostaglandins. Two enzyme isoforms of 
COX are known, referred to as COX-1 and COX-2, they are encoded by separate genes, and they have 
very  similar  structural  and  kinetic  properties  and  show  distinct  cell-specific  expression  and 
regulation [4].  COX-1  is  constitutively  expressed  in  most  tissues  and  plays  a  role  in  various 
physiologic functions, whereas COX-2 is transiently inducible by stimuli such as cytokines, growth 
factors,  mitogens,  tumor promoters and hormones and also regulates inflammation, differentiation, 
mitogenesis, and angiogenesis [4–7]. 
Recently,  a  concerted  effort  has  been  focused  on  COX-2  selective  inhibitors  since  COX-2 
expression  is  a  characteristic  feature  of  most  malignant  neoplasms.  Research  primarily  has 
demonstrated that COX-2 is up-regulated in a range of cancers, particularly colorectal cancer [3], but 
also  gastric  [5],  breast  [8],  thyroid  [9],  and  ovarian  cancers  [10–12].  Moreover,  elevated  COX-2 
expression has been identified as an independent prognostic factor [10] that is associated with reduced 
survival [11] and poor response to standard combination chemotherapy in ovarian cancer [12]. By 
using COX-2 selective inhibitors featuring disruption of the gene encoding this enzyme, relevance to 
carcinogenesis  in  various  organs,  including  the  ovarian,  has  been  shown  [6,13,14].  Possible 
involvement of COX-1 in ovarian cancer has also been reported. Daikoku T. et al. [15] found COX-1 
to  be  the  predominant  COX  isoforms  expressed  in  ovarian  cancer.  Studies  have  shown  that 
overexpression of COX-1 is associated with elevated levels of angiogenic factors in ovarian carcinoma, 
which  was  inhibited  by  COX-1  selective  inhibitors  [16].  These  results  indicate  that  the  COX 
participates in the progression of ovarian carcinoma and could be targeted for anti-tumor therapy. 
NSAIDs are thought to impede cancer growth primarily by attenuating COX activity, although other 
non-COX targets can not be ruled out. The effects of COX-1 selective inhibitors in attenuating tumor 
growth in vivo are remarkable [15], whereas, COX-2 selective inhibitors have potent antineoplastic 
effects in vivo in preclinical models of various solid malignancies [3,10]. These findings led to the 
initiation of a number of animal  and clinical  trials examining the efficacy of COX-1 and COX-2 
selective  inhibitors  in  primary  and/or  secondary  prevention  of  cancer  or  as  part of a combination 
therapy regimen for established tumors [3,17]. Many, but not all studies show that long-term use of 
NSAIDs reduces the risk of cancer [17,18]. Regular use of ibuprofen or aspirin decreased breast cancer 
rates by about  50% and 40%, respectively [18]. It appears that NSAIDs use significantly protects 
against some but not all types of human cancer. However, epidemiologic studies examining whether 
NSAIDs can prevent or delay the development of ovarian cancers remain inconclusive. Int. J. Mol. Sci. 2011, 12                       
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In the present study, we postulate that a combination of COX-1 and COX-2 selective inhibitors 
should reduce the growth of tumors more effectively than either agent alone in nude female mice 
transplanted with a human ovarian cancer SKOV-3 cell line. To test this possibility, combined effects 
of SC-560, a COX-1 selective inhibitor, and celecoxib, a COX-2 selective inhibitor, on ovarian tumor 
growth in vivo were examined. In addition, we also examined the anti-tumor mechanisms by which 
SC-560 and celecoxib affects ovarian cancer tumor growth. 
2. Results and Discussion 
2.1. Inhibition of Ovarian Cancer Growth 
To  test  whether SC-560 or celecoxib  could  inhibit ovarian cancer growth,  we used the human 
ovarian carcinoma cell line SKOV-3. SKOV-3 cells were implanted into the subcutaneous growth, so 
that changes in tumor growth could be easily monitored. The tumor growth increased throughout the 
period  examined  in  the  control  group  whereas  the  growth  was  substantially  suppressed  in  the 
combination group. Data in Figure 1 show the relative effect of SC-560 or/and celecoxib therapy. 
SC-560 or celecoxib administrated alone by gavage twice every other day for 21 consecutive days at 
3 mg/kg  body  weight,  25  mg/kg  body  weight  respectively  did  not  prevent  the  growth  of  ovarian 
carcinoma, but they both showed a decreasing tendency in growth-inhibitory effect compared with the 
control group. For example, after three weeks of treatment with SC-560, a mean tumor volume of 
966 mm
3 was observed on day 28. Under similar conditions, celecoxib-treated animals showed a mean 
tumor volume of 948 mm
3, whereas mean tumor volume in control mice was 1118 mm
3. The effects of 
SC-560  combined  with  celecoxib  in  attenuating  tumor  growth  are  remarkable  during  the  entire 
treatment  period.  On  day  28,  tumor  volume  in  the  combination  group  was  reduced  by  35.54% 
compared with control mice; the inhibitory effect of the combination group is significant statistically 
compared with that of control group (P < 0.05). These results suggest that the combination of COX-1 
and COX-2 selective inhibitors may have chemopreventive properties on ovarian cancer. 
2.2. Synergistic Effects of SC-560 and Celecoxib on Ovarian Cancer Growth 
SC-560  and  celecoxib  alone  showed  inhibition  of  tumor  growth  by  13.57%  and  15.16%, 
respectively,  in  this  experiment.  However,  a  combination  of  SC-560  and  celecoxib  showed  better 
antitumor activity with about 35.54% inhibition of tumor growth. Table 1 summarizes relative tumor 
volume of control and treated groups at three different time points. Combination therapy showed more 
than  additive  effect  on  tumor  growth  inhibition.  On  day  17,  there  was  1.2-fold  improvement  in 
antitumor activity in the combination group when compared with the expected additive effect. At this 
time point, celecoxib alone inhibited tumor growth by 8% (fractional tumor volume, 0.923 mm
3) when 
compared  with  the  control  group.  With  time,  there  was  a  progressive  improvement  in  antitumor 
activity. On day 24, SC-560 and celecoxib combination group showed a 1.4-fold higher inhibition of 
tumor growth over additive effect (expected fractional tumor volume). Int. J. Mol. Sci. 2011, 12                       
 
 
671 
Figure  1. Effects of SC-560 and celecoxib on tumor growth in vivo. The inhibitory of 
SC-560 and celecoxib on tumor growth were determined in an ovarian cancer model using 
SKOV-3 cells. After 7 days to allow tumor establishment, mice were treated with SC-560 
and celecoxib. Treatment was continued for 21 days. Average tumor volume in SC-560 and 
celecoxib  combination  group  was  significantly  different  from  vehicle-treated  mice  at  
day 28. Statistical significance was determined using Student’s t-test. * P < 0.05. 
 
Table 1. Combination therapy with SC-560 and Celecoxib. 
Day 
b 
Fractional Tumor Volume (FTV) Relative to Untreated Controls 
a 
SC-560  Celecoxib 
Combination 
Treatment 
Ratio of Expected 
TV/Observed FTV 
d 
Expected 
c  Observed   
17  1.027  0.923  0.948  0.807  1.175 
21  0.988  0.880  0.869  0.704  1.234 
24  1.036  0.949  0.983  0.700  1.404 
a FTV (mean tumor volume experimental)/(mean tumor volume control). 
b Day after tumor cell 
transplantation. 
c (Mean FTV of SC-560) ×  (mean FTV of Celecoxib). 
d Obtained by dividing the 
expected FTV by the observed FTV. A ratio of >1 indicates a synergistic effect, and a ratio of <1 
indicates a less than additive effect. 
2.3. COX Expression in Ovarian Carcinoma Cells 
To investigate whether the COX inhibitors can regulate COX-1 or COX-2 expression in ovarian 
carcinoma, the combination group and control  group were analyzed for expression of both COXs 
expression by Western blotting. Western blotting analyses of COXs expression show that the levels of 
COX-1 and COX-2 protein expression are reduced in the combination group compared with the control 
group (Figure 2). Moreover, the levels of COX-1 protein expression are substantially reduced in the Int. J. Mol. Sci. 2011, 12                       
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combination group compared with the control group (31% reduction, P < 0.01, Figure 3). Whereas the 
levels of COX-2 protein in the combination group only revealed a 24% diminution compared to the 
control group. 
Figure 2. COX protein levels in xenograft tumors of nude mice treated or not treated with 
combined  treatment  of  SC-560  and  celecoxib.  COX-1  and  COX-2  protein  levels  were 
analyzed  by  Western  blotting.  Anti-β-actin  was  used  as  a  control  for  equal  loading. 
Lanes 1–6: tumor tissues of six mice in control group. Lanes 7–12: tumor tissues of six 
mice in the combination group. 
 
Figure  3.  The  ratios  of  COX-1/actin  after  autoradiography  integrations.  Results  were 
expressed in arbitrary units. The COX-1 expression was decreased significantly by 31% in 
the  combination  group  compared  with  the  control  group  (*  P  <  0.01;  error  bars 
indicate SE). 
 
2.4. Cell Proliferation 
We employed cell growth in allografted tumors in nude mice treated with vehicle SC-560, celecoxib 
or SC-560/celecoxib, assessed by proliferation-associated nuclear antigen (Ki-67) staining. As shown 
in Figure 4A, the population of Ki-67-positive cells in tumor sections was substantially lower when the 
mice were exposed to SC-560/celecoxib than in those receiving the vehicle. Data for the proliferation 
index of four groups are shown in Figure 4B. In SC-560 or celecoxib alone group, the proliferation 
index were 16.67 ±  3.13% or 12.40 ±  2.92%, which are significant statistically compared with that of Int. J. Mol. Sci. 2011, 12                       
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the control group (22.56 ±  7.62%, both P < 0.05). Furthermore, the combination group showed a 
45.04% reduction of the proliferation index (12.40 ±  2.92%) at the end of treatment compared with the 
control group (P < 0.01). 
Figure 4. Cell proliferation in xenograft tumors of nude mice treated or not treated with 
SC-560  and/or  celecoxib.  (A)  Immunostaining  of  cell  proliferation  (Ki-67)  by 
immunohistochemistry. The combination group of COX selective inhibitor SC-560 and 
celecoxib  attenuates  tumor  cell  proliferation.  (B)  The  index  of  cell  proliferation  was 
determined from the ratio of nuclear Ki-67 protein-positive cells/total nuclei number by 
immunohistochemical method. * P < 0.05, ** P < 0.01, compared with control; error bars 
indicate SE. 
 
 
2.5. Cell Apoptosis 
We also employed cell apoptosis in these four groups, assessed by TUNEL. As shown in Figure 5A, 
the number of apoptotic cells was more frequent in tumor sections of the combination group than in 
those of the control group. Data for the apoptosis index of four groups are shown in Figure 5B. The 
apoptosis index was 25.63 ±  7.58% or 29.94 ±  7.88% in SC-560 or celecoxib alone group, which is 
significant statistically compared with that of the control group (19.07 ±  16.36%, both P < 0.05). In Int. J. Mol. Sci. 2011, 12                       
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addition, the combination group showed a 167.6% increase of the apoptosis index (51.03 ±  14.75%) at 
the end the treatment compared with the control group (P < 0.01). 
Figure 5. Cell apoptosis in xenograft tumors of nude mice in either the presence or absence 
of SC-560 and/or celecoxib. (A) Immunostaining of cell apoptosis in tumors by TUNEL. 
The combination group of COX selective inhibitor SC-560 and celecoxib accelerates tumor 
cell apoptosis. (B) The index of cell apoptosis was determined from the ratio of nuclear 
apoptosis-positive  cells/total  nuclei  number.  *  P  <  0.05,  **  P  <  0.01,  compared  with 
control; error bars indicate SE. 
 
 
2.6. Discussion 
The present study was conducted to assess how tumor development is modified by COX selective 
inhibitors. This study demonstrates that SC-560 and celecoxib, when administered together, resulted in 
a synergistic anti-tumor effect when compared with treatment with the same doses of either SC-560 or 
celecoxib alone, which highly significantly suppressed tumor growth compared with the control group 
on day 28. The effects of SC-560 combined with celecoxib in attenuating tumor growth in vivo proved 
remarkable during the entire treatment period. These results demonstrate that the combination of the 
two drugs enhances the antitumor activity against ovarian tumor. We have known in several previous Int. J. Mol. Sci. 2011, 12                       
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studies that, indeed, these combination protocols can provide greater efficacy than the individual agents 
administered  alone  [19,20].  It  is  anticipated  that  the  administration  of  a  combination  of 
chemopreventive agents, which are selected based on definitive mechanisms relevant to tumorigenesis, 
should have beneficial applications in human cancer chemoprevention trials. Likewise, COX inhibition 
procedures are now being examined for the preclinical treatment of tumor [15,16]. Inhibitors of COX-1 
are being shown to be more effective in improving tumor responsiveness when combined with other 
agents  [21]. Whereas  Shipeng Z.  et  al. [22] found that celecoxib  could inhibit tumor growth and 
enhance the antitumor effects of oxaliplatin through their synergistic role in inhibiting different targets 
in vivo. Our results strongly support the consideration and development of protocols to evaluate the 
preclinical efficacy of combining COX-1 inhibitor with COX-2 inhibitor therapy. In the present study, 
both  COX  inhibitors  were  given  together  in  a  fixed  schedule  and  dose.  Therefore,  the  observed 
synergism can be further improved by modulating dosage and frequency of administration based on 
pharmacokinetics, distribution, and bioavailability. 
Epidemiological and clinical studies have collectively identified COX-1 and COX-2 as molecules 
involved in the onset and progression of a variety of malignancies [2]. COX-1 and COX-2 inhibitors 
were reported to suppress tumor growth and metastasis in mice with established metastatic mammary 
tumors  [23]  and  intestinal  carcinoma  [19].  Moreover,  selective  or  nonselective  COX  inhibitors 
suppressed  tumor  growth  and  metastasis  in  mice  with  established  epithelial  ovarian  cancer  [24], 
modulating tumor angiogenesis improved survival of mice in mouse model of colorectal cancer [25]. It 
was reported that in APC (adenomatous polyposis coli) mice, which serve as a genetically defined 
model of FAP (familial adenomatous polyposis), the combination treatment with COX-1 and COX-2 
selective  inhibitors  more  effectively  suppressed  polyp  growth  than  either  of  the  single  treatments 
alone [19].  Additional  evidence  that  a  combination  therapy  approach  using  a  COX-1  and  a  COX 
inhibitor was more effective than either procedure alone at producing short-term tumor cures is shown 
in [20]. Li S. et al. [26] found that COX-1 and COX-2 are expressed in every type of ovarian epithelial 
cancer. Thus, both COXs may contribute to tumorigenesis in various organs. 
In this study, in comparison to the combination group, SC-560 or celecoxib alone led to less tumor 
inhibition during the entire treatment period, only showing decreasing tendency in growth-inhibitory 
effect of human ovarian SKOV-3 tumors compared to those with the control. This result differed from 
previous studies which reported administered COX-1 and COX-2 selective inhibitor alone could highly 
significantly decrease tumor growth [6,15]. The discrepancies may depend on difference in dosage and 
frequency of administration. 
Unrestricted cell proliferation and reduced apoptosis are hallmarks of transformed cells. A plethora 
of signaling pathways and molecules influences these processes. Our results of reduced tumor growth 
with  decreased  cell  proliferation  and  accelerated  apoptosis  following  the  combination  treatment 
suggest that COXs inhibitors suppress ovarian tumor growth at least by influencing cell proliferation 
and  apoptosis.  Inhibition  of  cell  proliferation  and  the  induction  of  apoptosis  are  believed  to  be 
responsible,  in  part,  for  the  chemo-preventative  effects  of  NSAIDs  illustrated  in  many 
reviews [15,27,28]. It was reported that SC-560 and celecoxib were both effective at inhibiting the 
growth  of  COX-deficient  HCT-15  colon  cancer  xenograft  in  nude  mice  and  induced  apoptosis 
in vitro [29]. Furthermore, Frank G. et al. [28] found that the SC-560 induce apoptosis and inhibit Int. J. Mol. Sci. 2011, 12                       
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tumor growth in vivo, and one mechanism may involve changes in gene expression by COX inhibitors 
which is dependent on the structural character of the COX selective inhibitor rather than its ability to 
selectively inhibit COX-1 and COX-2. This is in agreement with Zhu et al. who reported that NSAIDs 
induce apoptosis independent of their ability to inhibit COX [30]. Therefore, both COX-dependent and 
independent  mechanisms  are  probably  involved  in  the  chemo-preventative  activity  of 
these compounds. 
The  COX  isoforms  possibly  compensate  for  lack  of  expression  of  the  other  [31].  Dual-COX 
inhibition would be expected to overcome such compensation in ovarian tumorigenesis and this may be 
one of the reasons for the combination effect. However, most traditional COX inhibitors, such as 
indomethacin  are  more  potent  inhibitors  of  COX-1  than  COX-2.  Recently,  a  majority  of  tumors 
overexpresses  COX-2  and  not  COX-1;  this  is  consistent  with  the  hypothesis  that  COX-1  is 
constitutively expressed and responsible for basal, whereas COX-2 is highly inducible and responsible 
for pro-inflammatory cytokines and growth factors, both of which are likely to be highly concentrated 
within the microenvironment of a tumor. The basis for the divergent expression patterns of COX-1 and 
COX-2 in ovarian cancer is not known. In this experiment, we observed that both COXs protein levels 
were reduced in the combination group cells compared with those in the control group, but the levels of 
COX-1 proteins were markedly inhibited by SC-560 combined with celecoxib in tumor cells, which 
suggests that oncogenic transformation leads to the expression of COX-1 in the ovarian tissue. Similar 
results  were  obtained  by  Daikoku  T.  et  al.  [15,24].  Moreover,  Hales  D.B.  et  al.  [32]  and  
Urick M.E. et al. [33] both found high expression of COX-1, not COX-2, in ovarian cancer in the 
domestic hen (Gallus domesticus); others confirmed COX-1 expression but not COX-2 expression in 
SKOV-3  tumors  [34].  Dore  M.  et  al.  [35]  used  immunohistochemistry  to  demonstrate  strong 
expression of COX-1, not COX-2, protein in human ovarian cancer specimens. It was reported that 
COX-1 expression regulates angiogenesis in endothelial cell [36]. Induced overexpression of COX-1 in 
endothelial cells leads to malignant transformation [37]. These findings suggest COX-1 may be the 
predominant pathway compared with COX-2 in the development of ovarian cancer. 
3. Experimental Section  
3.1. Human Ovarian Tumors in Nude Mice 
SKOV-3 cells were used for tumor growth studies in vivo. SKOV-3 was purchased from China 
Type Culture Collection and grown in the recommended media under standard conditions. SKOV-3 
cells were implanted sub cutaneously in the dorsal skin (2 ×  10
6 cells) of female athymic nude mice 
(nu/nu,  7–8  weeks  old).  When  the  tumors  became  visible  (7  days  after  inoculation),  mice  were 
randomly separated into four groups (six mice in each group): SC-560, celecoxib, SC-560/celecoxib 
and control. 
COX inhibitors, SC-560 (Sigma Chemical Co. St. Louis, MO, U.S.) and Celecoxib (Pfizer Co. 
Groton, CT, U.S.) were administered by gavage in a 0.5 ml suspension of 0.5% methylcellulose (Sigma 
Chemical Co. St. Louis, MO, U.S.) 0.025% Tween 20 (Sigma Chemical Co.) at a dose of 3 mg/kg  
(SC-560), 25 mg/kg (celecoxib) twice a day. The dose was chosen for their specificity in inhibiting 
COX isotypes [38]. SC-560 alone, celecoxib alone, or SC-560 in combination with celecoxib was each Int. J. Mol. Sci. 2011, 12                       
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given by gavage twice every other day. A control group of mice was treated with sterile PBS under 
similar conditions. Drugs or vehicle were administered for a period of 21 days, beginning on the day 
one week after the tumors became palpable. 
The tumor dimensions were measured twice a week using a linear caliper, and tumor volume was 
calculated using the equation V (mm
3) = a ×  b
2/2, where a is the largest diameter and b is the smallest 
diameter  [39].  Tumor  growth  was  evaluated  by  the  inhibition  rate  as  assessed  by  the  formula:  
IR  =  C − T/C ×  100%.  Where  IR  is  the mean inhibition  rate,  T  is  the mean tumor volume in  the 
treatment group, and C is the mean tumor volume in the control group. The animals were weighed 
weekly  throughout  the  experiment.  On  day  28,  all  of  the  mice  were  sacrificed,  and  tumor  tissue 
samples  were  collected  and  then  fixed  in  10%  phosphate-buffered  formalin  solution  for 
immunohistology or stored at −80 °C  until analyzed. The tumor tissue samples were snap-frozen in 
liquid nitrogen before their storage at −80 ° C. 
3.2. Western Blot Analysis 
Lysates (40 µg of protein/lane) were analyzed by SDS-PAGE on 12% Tris-glycine gels. Protein was 
electrotransferred to nitrocellulose membranes and blocked with a solution of PBS containing 5% milk 
and 0.1% Tween 20. Bands were detected using chemiluminescent detection reagents (GE healthcare, 
code:  RPN2106).  Blots  were  probed  with  a  goat  polyclonal  antibody  against  COX-1  (Beijing 
biosynthesis biotechnology Co., China, code: bs-0582R), COX-2 (Beijing biosynthesis biotechnology 
Co., China, code: bs-0732R) followed by a peroxidase-conjugated antigoat (abcam), respectively. After 
incubation,  antibodies  were  washed  in  PBS  and  0.1%  Tween  20.  Bands  were  detected  using 
chemiluminescent detection reagents (GE healthcare, code: RPN2106). 
3.3. Immunohistochemistry 
Immunobiochemical  and  molecular  biologic  characterization  of  the  cell  proliferation-associated 
nuclear antigen is defined by monoclonal antibody Ki-67. Immunostaining with monoclonal antibody 
Ki-67 provides a reliable means of rapidly evaluating the growth fraction of normal and neoplastic 
human or animal cell populations. To detect the Ki-67 nuclear antigen, which is present throughout the 
cell  cycle,  but  absent  in  the  dormant  G0  phase  [40],  tumors  were  fixed  in  10%  neutral  buffered 
formalin  for  24–48  h  prior  before  being  embedded  in  paraffin.  After  deparaffinization,  the  tissue 
sections were heated at 121 ° C for 15 min in 10 mM TrisHCl with 1 mM EDTA (pH 9.0). Endogenous 
peroxidase was blocked with 3% hydrogen peroxide in methanol for 10 min at room temperature. The 
samples  were  incubated  with  anti-Ki-67  antigen,  clone  MIB-5  (M7248),  for  90  min  at  room 
temperature. Then, the sections were incubated in EnVision reagent for 40 min and DAB/H2O2 for  
8–12 min at room temperature. Proliferation was assessed by counting the number of Ki-67 positively 
staining nuclei and total number of cancer cells at × 400 magnification in five representative regions of 
the tumor. The proliferation index was calculated as follows: proliferation index = (number of cells 
labeled with Ki-67/total cell number) ×  100%. Int. J. Mol. Sci. 2011, 12                       
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3.4. TUNEL Assay 
Apoptosis can be measured in the terminal transferase uridyl nick end labeling (TUNEL) assay by 
the  TUNEL  kit  (Chemicon  Co.  Beijing  zhongshan,  China).  TUNEL  assay  allows  the  easy 
demonstration  of  cell  death  as  a  result  of  apoptosis.  The  tissue  samples  were  fixed  in  4% 
paraformaldehyde for 24 h, dehydrated, and embedded in paraffin in the conventional manner. The 
paraffin-embedded  tissues  were  cut  into  4-lm-thick  sections.  After  deparaffinization  in  a  graded 
alcohol series, the tissue sections were covered with 20 µg proteinase K⁄mL PBS(−) for 15 min at room 
temperature,  followed  by  blocking  of  endogenous  peroxidase  activity.  The  samples  were  then 
incubated  with  TdT  enzyme  and  biotin-16-dUTP  in  TdT  buffer  containing  0.01%  bovine  serum 
albumin  for  1.5  h  at  37  ° C  in  a  humidity  chamber.  Biotin-16-dUTP  nucleotides  that  had  been 
incorporated into DNA fragments were detected using the ABC method with DAB as the chromogen. 
In each tissue specimen, five high-power fields (× 400) were randomly selected; the apoptotic index 
was calculated in these fields as the percentage of positive cells, given by the following equation: 
apoptotic index = (number of positive cells/total number of cells) ×  100% [41]. 
3.5. Statistical Analyses 
Statistical  analysis  was  performed  with  SPSS  software  (SPSS  Standard  version  17.0,  SPSS). 
Statistical significance between control and treated groups was determined by Student’s t-test. All the 
experimental  data  were  expressed  as  means  values  ±   SE.  Results  were  considered  statistically 
significant when P values < 0.05. 
4. Conclusions  
The main finding of this study is that a combination therapy approach using SC-560 and celecoxib 
was  more  effective  than  either  procedure  alone  on  human  ovarian  SKOV-3  carcinoma  cells 
xenograft-bearing mice at producing short-term tumor cures. The data showed that the combination use 
of  SC-560  and  celecoxib  suppressed  tumor  growth  at  least  by  inhibiting  cell  proliferation  and 
increasing apoptosis. Our results also indicate that, COX-1 may be the predominant pathway compared 
with  COX-2  on  ovarian  cancer  in  the  effect  of  combination  use  of  COX-1  and  COX-2  selective 
inhibitors.  These  observations  support  the  hypothesis  that  a  combination  of  COX-1  and  COX-2 
selective  inhibitors  may  have  better  chemopreventive  properties  on  ovarian  cancer  than  when 
administered alone. 
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